Ellex has partnered with STAAR Surgical in Australia and New Zealand to bring you the most innovative refractive and cataract lens solutions available today

The EVO Visian ICL has transformed vision correction. Not only can it be used for a wider treatment range of myopia than traditional LASIK and other refractive procedures but it is also minimally invasive. More than 1,000,000 EVO Visian ICL lenses have been implanted worldwide.

STAAR Header image

EVO VISIAN ICL

Why Choose EVO Visian ICL?

Made from biocompatible Collamer, the EVO Visian ICL is one of the latest technological advancements in vision correction. The EVO Visian ICL is a long-lasting solution for refractive error and offers excellent quality of vision.

The surgical procedure for the EVO Visian ICL is similar to the procedure used to implant IOLs for the treatment of cataracts except the EVO Visian ICL rests in front of the eye's lens, leaving it intact.

EVO Visian ICL functions to focus light properly back onto the retina in a similar way glasses and contact lenses do. The EVO Visian ICL is placed into a space of the eye directly behind the iris (the colored part of the eye) and in front of the natural lens. In this position, the EVO Visian ICL functions to focus light properly onto the retina helping create clear distance vision.

FOR MORE INFORMATION, VISIT https://au.discovericl.com/

If you would like to schedule a training session with one of our clinical trainers or to learn more about EVO Visian ICL, please contact us below:


ABOUT STAAR

Since its inception in 1982, STAAR Surgical Company has revolutionized the industry with its development and use of Collamer. Each Collamer lens from STAAR is highly durable and replicates the eye's natural lens to create high-quality vision and optimal biocompatibility. With the introduction of the Visian Iens (ICL), STAAR has transformed the refractive market.

STAAR sells EVO Visian ICL and Visian ICL family of lenses in more than 75 countries, and it has been implanted in more than 1,000,000 eyes worldwide.

To learn more about STAAR, please visit www.staar.com

Contact us

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More

QUANTEL MEDICAL COMPLETES ACQUISITION OF ELLEX

Quantel Medical has completed its acquisition of Ellex, including the company’s laser and ultrasound technology solutions (with the exception of 2RT® and iTrack®), via the financial holding company Lumibird Medical.

The coming together of these two companies—both renowned in the field of ophthalmology—represents a real milestone in their history. Quantel Medical and Ellex have a shared heritage in the development of cutting-edge technologies for the diagnosis and treatment of the leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy.